Medical Uses of Doxorubicin

Doxorubicin is a highly effective chemotherapy medication used in the treatment of various types of cancer. It belongs to the anthracycline and antitumor antibiotic family of medications and is renowned for its potent antineoplastic properties.

Browse all Doxorubicin products

Mechanism of Action

Doxorubicin exerts its primary mechanism of action through multiple processes that disrupt DNA function and inhibit cancer cell growth. One key aspect is its ability to intercalate DNA base pairs. This intercalation disrupts the normal DNA structure and impairs the ability of DNA to function properly. By inserting itself into the DNA molecule, doxorubicin inhibits the activity of topoisomerases, particularly topoisomerase II. Topoisomerases are enzymes responsible for unwinding and rewinding DNA during the replication and repair processes. Inhibition of these enzymes prevents DNA from being properly replicated and repaired, leading to DNA damage accumulation in cancer cells.

Moreover, when doxorubicin interacts with iron in the body, it can generate reactive oxygen species (ROS). These ROS act as free radicals and cause oxidative damage to DNA. This oxidative damage further disrupts DNA synthesis and contributes to the cytotoxic effects of doxorubicin. However, it is important to note that the formation of free radicals can be mitigated by iron chelators like dexrazoxane. Iron chelators bind to iron, preventing its interaction with doxorubicin and reducing the formation of ROS, thereby potentially minimizing the risk of oxidative DNA damage.

Figure 1. The potential mechanisms of doxorubicin-mediated cell death.
(Source: Yang, F. et al., 2014)

Side Effects of Doxorubicin

Doxorubicin, a chemotherapy drug, can cause various adverse reactions. These include fatigue, hair loss (alopecia), nausea, vomiting, and mouth sores. It can also suppress bone marrow function and increase the risk of secondary malignancies. If doxorubicin leaks outside the vein during intravenous administration, it can cause severe tissue damage and necrosis.

One significant concern with doxorubicin is its cardiac toxicity, which limits its long-term use. The mechanism of doxorubicin-induced cardiac toxicity is different from its antitumor effects. It involves increased oxidative stress, down-regulation of cardiac-specific genes, and the induction of cardiac cell death (apoptosis). Acute cardiac toxicity, occurring within days of administration, can lead to reversible myopericarditis, left ventricular dysfunction, or arrhythmias.

Chronic, late cardiac toxicity is the most serious and potentially lethal adverse effect of doxorubicin. It can lead to irreversible cardiomyopathy and congestive heart failure. Various factors increase the risk of congestive heart failure, such as high cumulative drug doses, extremes of age, combination chemotherapy with other cardiotoxic drugs, hypertension, and pre-existing heart dysfunction. The mortality rate within one year of congestive heart failure development after doxorubicin treatment is approximately 50%.

It is crucial to monitor patients closely for cardiac toxicity during and after doxorubicin treatment. Healthcare professionals may employ various strategies to mitigate these risks, such as monitoring cardiac function, adjusting the dosage, or using cardioprotective agents. In recent years, liposomal formulations of doxorubicin have been developed to improve its therapeutic profile. These formulations have shown improved efficacy and reduced toxicity compared to conventional doxorubicin formulations.

Doxorubicin-Related Antibodies

Doxorubicin-Related Antigens